A Practical Guide to Implementing the Bribery Act in the Life Sciences Sector | 2 April 2012

Feb. 17, 2012 - PRLog -- The development and maintenance of products for the life sciences sector requires virtually permanent (and increasing) ongoing interactions with healthcare professionals. This includes post-market clinical follow-up studies, pharmacovigilance, health technology assessments, reimbursement discussions and the development of new products. As these needs grow in the future, companies need to reconcile such demands with the draconian nature of the new Bribery Act - described as the FCPA on steroids.

As reiterated by the recent multimillion dollar fines imposed on J&J, bribery allegations must be considered throughout the product lifecycle, and even in M&A transactions. This masterclass will summarise the law and the interaction with the ABPI Code of Practice. In addition, implications of the historic Memorandum of Understanding, published by the ABPI
and PMCPA in consultation with the SFO, will also be discussed.

To view the conference programme and full speaker line-up, visit http://www.smi-online.co.uk/briberyact14.asp

Alternatively, contact Vinh Trinh on +44 (0) 20 7827 6140 or email vtrinh@smi-online.co.uk

# # #

The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi's highly targeted conferences, workshops and publications.